Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 467Neoplasms 315Carcinoma, Non-Small-Cell Lung 269Prostatic Neoplasms 215Colorectal Neoplasms 207Lung Neoplasms 176Multiple Myeloma 123Melanoma 110Carcinoma, Renal Cell 107Ovarian Neoplasms 94Carcinoma, Hepatocellular 78Pancreatic Neoplasms 69Urinary Bladder Neoplasms 65Stomach Neoplasms 64Neoplasm Metastasis 64Leukemia, Lymphocytic, Chronic, B-Cell 62Colonic Neoplasms 59Leukemia, Myeloid, Acute 53Uterine Cervical Neoplasms 50Recurrence 49Liver Neoplasms 46Lymphoma, Follicular 45Lymphoma 45Leukemia, Myelogenous, Chronic, BCR-ABL Positive 39Esophageal Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Lymphoma, Large B-Cell, Diffuse 35Hematologic Neoplasms 35Head and Neck Neoplasms 35Lymphoma, Non-Hodgkin 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Bone Marrow Failure Disorders × Clear all
NCT04618081 2025-07-08

Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)

Celgene

Completed
151 enrolled
Lymphoid

Bone Marrow Failure Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡